The stock of Precigen Inc (NASDAQ: PGEN) rose to $7.33.This company has joined hands with its partner Precigen ActoBio to unveil details about the primary analysis in the Phase 1b/2a study. The results point out the possibility of the AG019 becoming an outstanding monotherapy to help patients struggling with  T1D. However, the […]